The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Janssen; Sanofi
A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).
 
Cora N. Sternberg
Honoraria - Astellas Pharma; AstraZeneca; Ipsen; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Ferring; Janssen; Lilly; MSD; Novartis
 
Fred Saad
No Relationships to Disclose
 
Julie Nicole Graff
Honoraria - Astellas Medivation; Bayer; Janssen Oncology
Consulting or Advisory Role - Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Oncoresponse: Exceptional responders
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Merck Sharp & Dohme
 
Avivit Peer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Janssen; MSD; Novartis; Pfizer; Roche
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Eugene Leung
Honoraria - Bayer
Research Funding - Bayer
Travel, Accommodations, Expenses - Actinium Pharmaceuticals
 
Eli Rosenbaum
No Relationships to Disclose
 
Howard Gurney
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst)
 
Richard Epstein
No Relationships to Disclose
 
Ian D. Davis
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Exelixis (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Bingyan Wu
Employment - inVentiv Health
 
Lucia Trandafir
Employment - Bayer
 
Volker Jean Wagner
Employment - Bayer; Merck
Stock and Other Ownership Interests - Amgen; Bayer; Merck
 
Maha Hussain
Honoraria - Onclive; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Sanofi